Mounjaro Regulatory Status: US, EU, Canada, UK

How Tirzepatide Works: The Dual-Incretin Mechanism

Tirzepatide is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. That dual-receptor activity sets it apart from every other incretin-based therapy on the market. The molecule activates both the GIP and GLP-1 receptors on pancreatic beta cells, gut epithelium, and hypothalamic appetite centers simultaneously.

GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. GIP receptor activation adds a complementary insulin-secretory signal and may independently influence fat metabolism. Preclinical data published in Cell Metabolism suggest GIP receptor signaling in adipose tissue promotes lipid storage capacity in subcutaneous depots and reduces ectopic fat deposition in visceral and hepatic compartments 1.

The practical result: in SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46% from baseline at 40 weeks, compared with 1.86% for semaglutide 1 mg. Mean body weight loss reached 12.4 kg with tirzepatide 15 mg versus 6.2 kg with semaglutide 1 mg 2. No other single-molecule injectable achieved both of those benchmarks in a head-to-head trial against semaglutide at the time of publication.

Tirzepatide's half-life of approximately 5 days supports once-weekly dosing. The 2.5 mg starting dose is titrated upward in 2.5 mg increments every 4 weeks based on glycemic response and tolerability, to a maximum of 15 mg weekly. This slow escalation schedule reduces the incidence and severity of gastrointestinal adverse events during initiation 3.

United States: FDA Approval Timeline

The FDA approved Mounjaro (tirzepatide) on May 13, 2022, for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults. This was the first regulatory clearance for tirzepatide anywhere in the world.

The approval was based on the SURPASS clinical program, which enrolled more than 9,000 participants across five Phase III trials. SURPASS-1 evaluated tirzepatide as monotherapy. SURPASS-2 compared it directly against semaglutide 1 mg. SURPASS-3 tested it against insulin degludec. SURPASS-4 compared it with insulin glargine in patients with high cardiovascular risk. SURPASS-5 examined it as add-on to insulin glargine 2.

Across all SURPASS trials, tirzepatide at the 5 mg, 10 mg, and 15 mg doses achieved statistically superior HbA1c reductions versus every active comparator tested. In SURPASS-3 (N=1,444), tirzepatide 15 mg reduced HbA1c by 2.37% versus 1.34% for insulin degludec at 52 weeks 4.

On November 8, 2023, the FDA separately approved Zepbound (tirzepatide) for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease 5. The Zepbound approval was supported by the SURMOUNT trial program. In SURMOUNT-1 (N=2,539), participants without type 2 diabetes who received tirzepatide 15 mg lost 22.5% of baseline body weight at 72 weeks, compared with 2.4% for placebo 6.

The FDA did not grant Mounjaro itself a weight-management indication. Prescribers who use Mounjaro for weight loss in patients without type 2 diabetes are prescribing off-label. Zepbound carries the obesity indication but is the same molecule at the same doses.

European Union: EMA Centralized Authorization

The European Medicines Agency (EMA) granted centralized marketing authorization for Mounjaro on September 15, 2022, making tirzepatide available across all 27 EU member states plus Iceland, Liechtenstein, and Norway through a single approval 7.

The EMA's Committee for Medicinal Products for Human Use (CHMP) based its positive opinion on the same SURPASS dataset submitted to the FDA. The approved EU indication is type 2 diabetes mellitus as an adjunct to diet and exercise. It can be used as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in combination with other glucose-lowering medicinal products.

A notable difference from the US label: the EMA summary of product characteristics explicitly addresses combination with basal insulin, SGLT2 inhibitors, and metformin, giving EU prescribers broader labeled flexibility for multi-drug regimens from the outset.

Eli Lilly submitted a separate application to the EMA for tirzepatide's weight-management indication in late 2023. The CHMP adopted a positive opinion for this indication in November 2024, and the European Commission granted formal marketing authorization for the obesity/overweight indication shortly afterward, with the product marketed under the name Mounjaro in most EU markets rather than a separate brand name 8.

Real-world EU rollout has been uneven. Germany, Denmark, and the Netherlands saw commercial availability within weeks of authorization. Other member states experienced delays tied to national pricing and reimbursement negotiations, a process that can add 6 to 18 months after EMA approval in some jurisdictions.

United Kingdom: MHRA Approval and NICE Assessment

The Medicines and Healthcare products Regulatory Agency (MHRA) approved Mounjaro for type 2 diabetes in September 2023. The UK had already exited the EU's centralized regulatory framework following Brexit, requiring a separate national review.

The more consequential step for UK patients was the National Institute for Health and Care Excellence (NICE) technology appraisal. NICE published its final guidance recommending tirzepatide as an option for type 2 diabetes in adults in 2024, subject to the standard restrictions: it must be used in combination with other glucose-lowering drugs when those drugs, together with diet and exercise, do not provide adequate glycemic control 9.

NICE appraisals determine whether the National Health Service (NHS) will fund a treatment. Without a positive NICE recommendation, a drug may hold MHRA approval but remain practically inaccessible to most UK patients through the NHS. Tirzepatide received a favorable cost-effectiveness determination after Eli Lilly submitted a confidential patient access scheme that reduced the effective price to the NHS.

For weight management specifically, a separate NICE appraisal is required. As of 2026, NICE has recommended tirzepatide for chronic weight management through specialist weight management services, building on the SURMOUNT trial evidence. NHS England has outlined a phased rollout plan for access through tier 3 and tier 4 weight management services.

"We consider tirzepatide to be a cost-effective use of NHS resources for adults with type 2 diabetes," the NICE appraisal committee stated in its final guidance document.

Canada: Health Canada Authorization

Health Canada approved tirzepatide (Mounjaro) in November 2023 for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults. The approval came through the standard New Drug Submission pathway 10.

The approved dose range mirrors the US and EU labels: 2.5 mg once weekly as the starting dose, titrated to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg based on clinical response. The Canadian product monograph carries the same boxed warning about thyroid C-cell tumors observed in rodent studies that appears on the US label, though no causal link has been established in humans.

Provincial drug plan coverage varies significantly across Canada. As of early 2026, several provinces including Ontario and British Columbia have added tirzepatide to their public formularies with prior authorization criteria that typically require documented failure of or intolerance to metformin plus at least one other oral glucose-lowering agent. Private insurance plans have been faster to add coverage, though many require step therapy through a GLP-1 receptor agonist before approving tirzepatide.

The weight-management indication for tirzepatide in Canada followed a separate regulatory submission. Health Canada approved tirzepatide for chronic weight management in 2025, making Canada one of the later G7 nations to grant this indication.

Regulatory Differences Worth Knowing

Each of the four regulatory jurisdictions made its assessment using the same core SURPASS clinical dataset, yet meaningful differences exist in how the drug can be prescribed and accessed.

The FDA label for Mounjaro restricts the indication to type 2 diabetes. Weight management requires prescribing Zepbound, which is the identical molecule sold under a different trade name and NDC number. The two-brand strategy lets Eli Lilly set different pricing and manage different insurance formulary pathways for each indication.

The EMA, by contrast, added the weight-management indication to the existing Mounjaro marketing authorization. EU prescribers use a single product name for both indications, simplifying pharmacy workflows but creating different reimbursement hurdles at the national level.

The MHRA and NICE processes are sequential rather than parallel, meaning UK patients face a longer path from regulatory approval to actual NHS prescriptions. A drug can sit approved but unfunded for months or even years. Tirzepatide moved through this process faster than average, partly because of the strong comparative efficacy signal versus existing GLP-1 receptor agonists.

Health Canada's provincial formulary system means that a federally approved drug may be covered in Alberta but not in Quebec, or vice versa, depending on each province's pharmacoeconomic review.

"Regulatory approval is the starting line, not the finish line," noted Dr. Daniel Drucker, a professor at the University of Toronto and one of the foundational researchers in incretin biology. "Access depends on pricing negotiations, formulary decisions, and clinical guideline updates that follow their own timelines."

The SURPASS and SURMOUNT Programs: Evidence Base for Approvals

Every regulatory decision for tirzepatide rests on two large clinical trial programs. Understanding what each program demonstrated explains why regulators in all four jurisdictions reached positive decisions.

The SURPASS program comprised five Phase III trials in type 2 diabetes. SURPASS-1 (N=478) tested tirzepatide monotherapy against placebo and showed HbA1c reductions of 1.87% to 2.07% across dose levels at 40 weeks 11. SURPASS-2 provided the head-to-head comparison against semaglutide that became the most-cited trial in the program. SURPASS-4 (N=2,002) was the cardiovascular safety trial, demonstrating non-inferiority to insulin glargine on major adverse cardiovascular events over a median follow-up of approximately 2 years 12.

The SURMOUNT program targeted obesity and overweight. SURMOUNT-1 established the 22.5% body weight reduction figure that drove Zepbound's FDA approval. SURMOUNT-2 (N=938) studied tirzepatide specifically in adults with type 2 diabetes and obesity, showing 14.7% mean weight loss with the 15 mg dose at 72 weeks versus 3.2% with placebo 13. SURMOUNT-3 and SURMOUNT-4 explored maintenance dosing after initial weight loss phases.

The cardiovascular outcomes trial SURPASS-CVOT is ongoing and aims to determine whether tirzepatide reduces major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Results are expected in 2027 and could trigger label updates across all four jurisdictions if the findings are positive.

Off-Label Use and Regulatory Gray Areas

Before Zepbound received FDA approval and before other regulators added obesity indications, tirzepatide was widely prescribed off-label for weight management. That practice has not entirely disappeared.

In the US, some prescribers continue to write Mounjaro prescriptions for weight loss rather than Zepbound prescriptions because insurance formulary placement or copay assistance programs may differ between the two brand names. This is legally permissible in the US, where physicians can prescribe any FDA-approved drug for any indication they deem clinically appropriate.

In the UK and EU, off-label prescribing is more tightly regulated. NHS prescribers generally cannot prescribe Mounjaro for weight management outside of the approved indication and the NICE-recommended patient population. Private clinics in the UK have filled some of this gap, but MHRA guidance discourages off-label dispensing through online pharmacies without adequate clinical oversight.

Canada occupies a middle position. Off-label prescribing is permitted, but provincial drug plans will not reimburse off-label use, placing the full cost on the patient or private insurer.

Supply Constraints and Market Availability

Regulatory approval does not guarantee pharmacy shelves are stocked. Tirzepatide has experienced intermittent supply shortages in all four markets since its launch.

The FDA placed tirzepatide on its drug shortage list in late 2022 and did not fully resolve all dose-strength shortages until mid-2024. The 2.5 mg and 5 mg KwikPen presentations were most affected, disrupting new patient starts more than existing patients on higher maintenance doses 14. During this period, the FDA allowed compounding pharmacies to produce tirzepatide under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Eli Lilly has since filed legal challenges against some compounders, and the FDA removed tirzepatide from the shortage list in 2024.

EU supply has been constrained by manufacturing ramp-up timelines. Eli Lilly's manufacturing facility in Research Triangle Park, North Carolina, and its newer facility in Concord, North Carolina (a $2.5 billion investment announced in 2023), are the primary global supply sites. Lilly also broke ground on additional manufacturing capacity in Ireland and Germany, with production expected to begin in 2026 or 2027.

In Canada and the UK, supply disruptions have tracked the US pattern with a slight lag. The intermittent unavailability of certain dose strengths has forced some clinicians to adjust titration schedules or temporarily switch patients to alternative GLP-1 receptor agonists.

What Comes Next: Pending Regulatory Actions

Several regulatory decisions could expand tirzepatide's global footprint in the next 12 to 24 months.

The SURPASS-CVOT results, expected around 2027, could add a cardiovascular risk reduction claim to the label if the trial meets its primary endpoint. Such a claim would mirror the path semaglutide took with the SELECT trial, which led to an expanded FDA indication in March 2024.

Regulatory applications for tirzepatide in heart failure with preserved ejection fraction (HFpEF) are anticipated based on the SUMMIT trial (N=731), which demonstrated that tirzepatide 15 mg improved the Kansas City Cardiomyopathy Questionnaire clinical summary score by 6.9 points more than placebo at 52 weeks in patients with obesity-related HFpEF 15.

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved tirzepatide for type 2 diabetes in 2022, and regulatory submissions in additional Asian and Latin American markets are in progress. Each new market approval adds manufacturing demand pressure, making supply chain capacity a rate-limiting factor for global access.

Prescribers treating patients across borders or managing care for patients who travel between the US, EU, UK, and Canada should confirm that the specific dose strength is available in the destination country. Dose presentation (KwikPen versus pre-filled syringe) may also differ by market, and patients should receive device training for any unfamiliar delivery system before traveling.